By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...